IEQ Capital’s Agios Pharmaceuticals AGIO Stock Holding History

IEQ Capital’s Portfolio AGIO Stock Details AGIO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q3	–	Sell	-8,086	Closed	-$269K	–	1835
2025 Q2	$269K	Buy	+8,086	New	+$245K	﹤0.01%	1456

Other funds holding AGIO

FCM

Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return

EAM

Erste Asset Management Vienna, Austria $10.8B AUM 38.54% 1-Year Est. Return

PBA

Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return

IEQ Capital's AGIO Position: Q3 2025 in Review

IEQ Capital sold out of Agios Pharmaceuticals (AGIO) in Q3 2025, closing a stake of 8,086 shares — an estimated $269K sold.

IEQ Capital first reported a position in AGIO in Q2 2025 and held it in 1 quarter. The position peaked at $269K in Q2 2025. 220 funds tracked by Wall St. Rank hold AGIO as of Q3 2025.

IEQ Capital reported no remaining Agios Pharmaceuticals position as of Q3 2025 after selling out during the quarter.
IEQ Capital sold 8,086 Agios Pharmaceuticals shares in Q3 2025, an estimated $269K.
IEQ Capital first reported a position in Agios Pharmaceuticals in Q2 2025 and held it in 1 quarter.
IEQ Capital's Agios Pharmaceuticals position peaked at $269K in Q2 2025.
220 funds tracked by Wall St. Rank held Agios Pharmaceuticals as of Q3 2025.

Based on IEQ Capital's 13F filing for Q3 2025, filed 14 Nov 2025.